NCT05213104View on ClinicalTrials.gov

Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Arrhythmia or Tachycardia

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

186

Participants

Timeline

Start Date

March 23, 2022

Primary Completion Date

February 28, 2024

Study Completion Date

July 31, 2026

Conditions
Patent Foramen OvaleAtrial ArrhythmiaCryptogenic Stroke
Interventions
DRUG

Flecainide

Flecainide 150 mg 6 months in addition to standard of care

DRUG

Flecainide

Flecainide 150 mg 3 months in addition to standard of care

Trial Locations (1)

75013

Hopital Pitié Salpetrière, Paris

All Listed Sponsors
collaborator

Fonds de Dotation ACTION

OTHER

lead

Assistance Publique - Hôpitaux de Paris

OTHER